ReviewCureus2025
Efficacy of Colchicine in Reducing Cardiovascular Events in Patients with Acute Coronary Syndrome: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Taming the Cytokine Storm: Therapeutic Strategies for Post-Acute Sequelae of SARS-CoV-2 Infection.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbidity and mortality, largely due to the high incidence of recurrent adverse events. Colchicine, a traditional anti-inflammatory drug primarily used for the treatment of gout, has emerged as a potential therapeutic option in cardiovascular care due to its ability to stabilize atherosclerotic plaques. This systematic review aimed to evaluate the efficacy of colchicine in reducing cardiovascular events and inflammatory biomarkers in patients with ACS. Eight studies published between 2013 and 2024 were included, selected through a comprehensive search of databases such as PubMed, ScienceDirect, Cochrane Library, and SciELO, as well as manual searches in scientific journals like the New England Journal of Medicine and via the Google Scholar search engine. Eligibility criteria included randomized, double-blind, placebo-controlled clinical trials assessing patients diagnosed with ACS. A total of 18,759 patients were analyzed, 9,369 in the intervention group (colchicine 0.5 mg/day plus standard treatment) and 9,390 in the placebo group, with follow-up periods ranging from three months to three years. Both primary outcomes (major cardiovascular events including myocardial infarction, stroke, and recurrent ischemia) and secondary outcomes (reduction of inflammatory biomarkers such as hs-CRP and IL-6 and incidence of adverse effects) were assessed. The results demonstrated that colchicine was associated with a significant reduction in hs-CRP and IL-6 levels, as well as a lower incidence of adverse cardiovascular events, particularly myocardial infarction and recurrent myocardial ischemia. In conclusion, colchicine may represent a promising adjunctive therapeutic alternative for patients with ACS, particularly due to its anti-inflammatory effects and potential role in secondary prevention. However, further studies with greater methodological consistency and long-term follow-up are required to confirm these benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.